SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant volatility as investors weigh the company's shift toward high-performance AI data center infrastructure against macro-driven sell-offs and geopolitical instability in the Middle East. While community sentiment remains polarized, many participants are focused on the company's execution timeline for new site energization and the potential for major hyperscaler contract announcements to serve as a catalyst for recovery.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the stock's long-term potential in the data center and AI infrastructure sector against macro-driven sell-offs linked to geopolitical tensions and debt concerns. While the community remains divided between those panic-selling and those adding to their positions ahead of upcoming earnings, sentiment is heavily focused on the anticipation of new hyperscaler lease announcements that could serve as a major catalyst for a price recovery.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying as investors position the stock as a primary 'bring-your-own-power' solution for the surging AI data center buildout, further fueled by recent policy discussions surrounding energy infrastructure independence. The community is actively debating the stock's valuation and volatility, while tracking technical breakout levels and watching for institutional accumulation as the company solidifies its role in the critical power generation sector.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is seeing heightened market attention as traders closely monitor the expected finalization of a multi-billion dollar debt financing deal, which is widely viewed as a critical catalyst for the firm's data center expansion. The stock's recent volatility has sparked intense debate among community members, who are actively balancing concerns over insider selling and high debt levels against the company's strategic partnerships and potential upside in the evolving AI infrastructure sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is seeing intense trading activity as investors react to ongoing speculation about an exit from conservatorship, with prominent figures like Bill Ackman and Michael Burry reportedly maintaining long positions. Community sentiment remains deeply divided, with bulls pointing to potential future catalysts and institutional buying, while bears emphasize the lack of concrete news and the stock's recent volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense downward pressure driven by a combination of geopolitical instability in the Middle East and market FUD surrounding Google's new memory-compression technology. While the community remains deeply divided between those viewing the current valuation as a generational buying opportunity and those fearing further technical breakdowns, investors are closely watching key support levels as they navigate the disconnect between the company's strong fundamentals and persistent institutional selling.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy is capturing significant market attention following its recent NASDAQ debut and business combination, as traders speculate on the potential for massive oil reserves in the Jameson Land Basin. The community is actively debating the company's long-term exploration goals versus short-term volatility, with many monitoring volume, potential squeezes, and the involvement of experienced industry leadership.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as investors weigh the impact of rising geopolitical tensions and energy prices against the semiconductor sector's role in a potential market recovery. The community remains deeply divided, with some traders aggressively buying the dip on the belief that a quick diplomatic resolution will spark a rebound, while others warn of a structural bear flag and further downside as bearish momentum builds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?

ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.

Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

Mizuho upped their price objective on BridgeBio Pharma from $91.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday...

Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO

Fred Alger Management LLC boosted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 729.3% during the 3rd quarter, according to the company in its most recent filing...

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an...

HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO

HighVista Strategies LLC grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 21.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO

Granahan Investment Management LLC boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 95.0% in the 3rd quarter, according to the company in its most recent 13F...

Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO

Boone Capital Management LLC bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a...

BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar discussed the company's late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a...

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease treatment.read more...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Current Price	$69.36
Prev Close	$69.70
Open	$69.68
Dividend Yield	0.00%
50-Day Moving Average	$71.86
Beta	1.32
Avg. Volume	3.65M
PE Ratio	-18.42

52-Week High	$84.94
52-Week Low	$28.33
Market Capitalization	$13.51B
EPS (Annual)	-$3.79
Price to Book	-6.51
Revenue Per Employee	$598,421.93

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BBIO News

BBIOBridgeBio Pharma Inc